(Q48164714)

9 February 2018

title

The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models (English)

1 reference

9 February 2018

0 references

Mi Young Jeon

1

1 reference

9 February 2018

Won Yong Lee

series ordinal

2

1 reference

9 February 2018

Ho Young Kang

series ordinal

3

1 reference

9 February 2018

Eun Joo Chung

series ordinal

4

1 reference

9 February 2018

publication date

1 April 2007

1 reference

9 February 2018

published in

Neurological Research

1 reference

9 February 2018

volume

29

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

289-295

1 reference

9 February 2018

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

cites work

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Neurotoxicity of levodopa on catecholamine-rich neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dopamine release in rat striatum after administration ofl-DOPA as studied with in vivo electrochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

The behavioural effects of pramipexole, a novel dopamine receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Pharmacology of dopamine agonists in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Levodopa therapy from the neuroprotection viewpoint. From a clinical outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F174313206X153996

21 January 2018

Identifiers

DOI

10.1179/174313206X153996

1 reference

9 February 2018

1 reference

9 February 2018